Many patients with strongly hormone receptor-positive tumors, including lobular cancers, may not respond to chemotherapy either clinically or by pathological response. In these patients, lack of response may not correlate with a worse long-term outcome to the same extent that it would in triple nega...

There are a lot of misconceptions regarding the value of neoadjuvant chemotherapy in ER-positive breast cancer. Downstaging disease to improve operability and breast conservation is one, but sometimes the objective is not clear. Response is low and value of neoadjuvant chemotherapy should be weighed...